Taiwan-based startup JelloX Biotech Inc. has entered into a collaboration through a know-how agreement with Mayo Clinic, in the US, to further develop and validate their 3D digital imaging and artificial intelligence (AI) analysis technology.

JelloX previously participated in the fifth cohort of the Mayo Clinic and Arizona State University Alliance for Health Care MedTech Accelerator, a flagship programme providing early-stage medical device and healthcare technology companies with curriculum to accelerate their go-to-market plans. JelloX has developed a 3D pathology imaging technology with AI for spatial analysis to support precision cancer diagnosis.

Cancer diagnosis using traditional 2D imaging methods can miss spatial relationships of critical tumor biomarkers and suffer from interpretive variability. JelloX's 3D imaging technology captures enhanced spatial context, providing a 3D view of tissue architecture that hopes to improve diagnostic accuracy and consistency and provide pathologists a more comprehensive diagnosis for cancer patients.

Furthermore, the same biopsy tissue can then be analysed by genomic sequencing and proteomics to provide patients with the full spectrum of precision medicine.

JelloX's CEO and founder, Dr. Yen-Yin Lin added, "Our goal is to provide researchers and clinicians with more precise diagnostic tools and to support pharmaceutical companies in their quest to develop new drugs to match patients with the right treatment at the right time."